These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28577987)

  • 21. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease.
    Alzoubi KH; Mokhemer E; Abuirmeileh AN
    Behav Brain Res; 2018 Sep; 350():109-115. PubMed ID: 29758248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.
    Kohl Z; Ben Abdallah N; Vogelgsang J; Tischer L; Deusser J; Amato D; Anderson S; Müller CP; Riess O; Masliah E; Nuber S; Winkler J
    Neurobiol Dis; 2016 Jan; 85():206-217. PubMed ID: 26523794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective effects of SCM198 on 6-hydroxydopamine-induced behavioral deficit in rats and cytotoxicity in neuronal SH-SY5Y cells.
    Shi XR; Hong ZY; Liu HR; Zhang YC; Zhu YZ
    Neurochem Int; 2011 Jul; 58(8):851-60. PubMed ID: 21093517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis.
    Ermine CM; Wright JL; Frausin S; Kauhausen JA; Parish CL; Stanic D; Thompson LH
    Hippocampus; 2018 May; 28(5):327-337. PubMed ID: 29431270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective activity of acetyl-L-carnitine: studies in vitro.
    Forloni G; Angeretti N; Smiroldo S
    J Neurosci Res; 1994 Jan; 37(1):92-6. PubMed ID: 7908343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
    Ferrigno A; Vairetti M; Ambrosi G; Rizzo V; Richelmi P; Blandini F; Fuzzati-Armentero MT
    Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):695-703. PubMed ID: 25904005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory function when cultured in spheroids.
    Berg J; Roch M; Altschüler J; Winter C; Schwerk A; Kurtz A; Steiner B
    Stem Cell Rev Rep; 2015 Feb; 11(1):133-49. PubMed ID: 25120226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2-regulated mitochondrial biosynthesis.
    Hota KB; Hota SK; Chaurasia OP; Singh SB
    Hippocampus; 2012 Apr; 22(4):723-36. PubMed ID: 21542052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma.
    Hart AM; Wiberg M; Youle M; Terenghi G
    Exp Brain Res; 2002 Jul; 145(2):182-9. PubMed ID: 12110958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.
    Yue P; Gao L; Wang X; Ding X; Teng J
    Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
    Yildirim FB; Ozsoy O; Tanriover G; Kaya Y; Ogut E; Gemici B; Dilmac S; Ozkan A; Agar A; Aslan M
    Neurochem Int; 2014 Dec; 79():1-11. PubMed ID: 25263280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model.
    Gu S; Huang H; Bi J; Yao Y; Wen T
    Brain Res; 2009 Feb; 1257():1-9. PubMed ID: 19111525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro 6-hydroxydopamine-induced toxicity in striatal, cerebrocortical and hippocampal slices is attenuated by atorvastatin and MK-801.
    Massari CM; Castro AA; Dal-Cim T; Lanznaster D; Tasca CI
    Toxicol In Vitro; 2016 Dec; 37():162-168. PubMed ID: 27647473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation.
    Barhwal K; Hota SK; Jain V; Prasad D; Singh SB; Ilavazhagan G
    Neuroscience; 2009 Jun; 161(2):501-14. PubMed ID: 19318118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
    Abdul HM; Calabrese V; Calvani M; Butterfield DA
    J Neurosci Res; 2006 Aug; 84(2):398-408. PubMed ID: 16634066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons.
    Bigini P; Larini S; Pasquali C; Muzio V; Mennini T
    Neurosci Lett; 2002 Sep; 329(3):334-8. PubMed ID: 12183043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.